Actonel
Company: Procter & Gamble, Hoechst Marion Roussel
Approval Status: Approved April 1998
Treatment for: Paget's Disease
Areas: Endocrinology; Hematology; Musculoskeletal
| General Information | Clinical Results |
General Information
Other Useful Resources
Actonel has been approved as a new therapy for treating Paget's disease of the bone.
Clinical Results
Approval is based on an 18-month, double-blind, active-controlled pivotal trial of 123 patients with moderate-to-severe Paget's disease, which showed disease remission in the majority of patients who received Actonel.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
Medical Dictionary Searches
